氨溴索联合肺力咳胶囊治疗COPD急性加重期的疗效观察

摘要

目的探讨氨溴索注射液联合肺力胶囊在慢性阻塞性肺疾病急性加重期（AECOPD）的临床疗效，并分析其发挥作用的具体机制。方法将74例AECOPD患者随机分为对照组（37例）和治疗组（37例），对照组给予抗感染、平喘、糖皮质激素等常规药物治疗，治疗组在对照组基础上加用氨溴索和肺力胶囊治疗，两组治疗周期均为21d。观察治疗前后两组患者临床症状及运动耐力改善的情况。结果治疗组和对照组治疗前后症状改善总有效率分别为86.5％和62.2％，差异有统计学意义（P＜0.01）；治疗后，治疗组患者运动耐力明显增强，显著优于对照组患者（P＜0.05）。结论氨溴索和肺力胶囊能有效改善AECOPD患者临床症状，并对患者运动耐力提升有帮助。%Objective To investigate the curative effect of combination ambroxol and Fei Li Ke capsules on acute exacerbation of chronic obstructive pulmonary disease, then explore the possible mechanism. Methods 74 acute exacerbation COPD patients were randomly divided into control group (37cases) and treatment group (37cases), the patients in control group were given the routine cure, including anti-infection,antiasthma and glucocorticoids using. Patients in treatment group were given combination ambroxol and Fei Li Ke capsules on the basic of routine cure. Both groups were treated for 21 days. The symptoms of the patients and movement function were observed. Results The overall effective rate of clinical symptoms of the treatment group and control group were 86.5%and 62.2%, there is statistical difference between them (P<0.01);After management for 21d, the movement function in treatment group has enhanced greatly compared to control group (P<0.05). Conclusion Combination ambroxol and Fei Li Ke capsules can improve clinical symptoms and enhance movement function in patients with a AECOPD.